Extended Data Fig. 5: Counts of clinically relevant molecular features observed in retrospective cohorts by MOAlmanac by cohort, feature type, evidence, and assertion type.
Counts of clinically relevant molecular features associated with therapeutic sensitivity, resistance, and prognosis categorized as putatively actionable (exactly matching a fully characterized genomic event catalogued in MOAlmanac) or investigate actionability (partial match) by evidence tier for metastatic melanomas (MEL, n = 110), metastatic castration-resistant prostate cancer (mCRPC, n = 150), kidney papillary renal-cell carcinoma (KIRP, n = 100), and osteosarcoma (OS, n = 59). Data is available as source data.
